SITC is pleased to announce the publication of our newest guideline, "Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immunotherapy for the treatment of gastrointestinal cancer."
Clinicians will find this guideline an invaluable resource to assist in navigating the challenging issues that sometimes arise during the treatment of gastrointestinal cancer, including treatment selection based on histology and biomarker status, toxicity management, and quality of life and patient education. This guideline covers immunotherapy for the treatment of esophageal, GE junction, gastric, duodenal and distal small bowel, pancreaticobiliary, colorectal, and anal cancer.
The manuscript, the latest in the ongoing series of SITC Cancer Immunotherapy Guidelines, is available now in the Journal for ImmunoTherapy of Cancer (JITC), the society’s open access, peer-reviewed online journal and a mobile version with interactive tools will be available in the SITC CPG Mobile App soon. Check the notifications in the app to be alerted when the mobile version of the guideline becomes available.
Key features of the new guideline include:
- Expert panel recommendations on diagnosis and initial staging, treatment selection, response monitoring and surveillance, and considerations for special patient populations.
- Immunotherapy treatment algorithms for advanced esophagogastric and colorectal cancer.
- Discussion of emerging immunotherapy strategies for multiple GI cancers, including MSS colorectal cancer.
- Quick-reference tables summarizing pivotal trial data for approved immunotherapy agents for GI cancer.